Abstract: A lithium secondary battery includes a negative electrode, a positive electrode positioned opposite to the negative electrode, a separator disposed between the negative electrode and the positive electrode, and a non-aqueous electrolyte, wherein the negative electrode includes a silicon-based active material, the silicon-based active material comprises a compound represented by SiOx, wherein 0?x<2, the non-aqueous electrolyte includes a lithium salt, an organic solvent, and an additive, the additive includes a first additive and a second additive, the first additive includes a coumarin-based compound represented by Formula 1, and the second additive includes at least one of lithium fluoromalonato(difluoro)borate (LiFMDFB), lithium difluoro(oxalato)borate (LiDFOB), lithium difluorophosphate (LiDFP), or lithium difluorobis-(oxalate)phosphate (LiDFOP): wherein R and n are described herein.

Abstract: Disclosed are a protein marker, indicative of an increase in differentiation into adipocytes, comprising an XBP1(S) having an amino acid sequence of SEQ ID NO. 1, 2 or 3, and the uses thereof in developing a promoter of adipocyte differentiation and a method for promoting adipocyte differentiation, a repressor of adipocyte differentiation and a method for repressing adipocyte differentiation, an agent and a method for screening a repressor of adipocyte differentiation, and a method for reducing rosiglitazone's side effect of causing obesity. Also, provided is a protein marker, indicative of an increase in differentiation into adipocytes, comprising an XBP1(U) having an amino acid sequence of SEQ ID NO. 4, 5 or 6. When targeting the XBP1(S) gene or protein, a compound capable of blocking or restraining differentiation into adipocytes can be used to develop an agent for the prevention and treatment of obesity.